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Introduction 
 
Innovations play a vital role for the firm regardless of the industry where company 
operates, and, the level of innovativeness considered as the one of the most important predictors 
of its performance, especially in the long term perspective [Torchia, Calabro, Huse, 2011]. 
Innovation is a key element in helping firms to find and develop a competitive advantage [Hitt, 
Hoskisson, Johnson, Moesel, 1996], expand market share, and increase their performance 
[Franko, 1989]. Many rankings [the Thomson Reuters Top 100 Global Innovators] regularly 
make the ranking of the most innovative firms in the world based on the analysis of patent-
related metrics that shows the importance of this factor. 
The level of innovative activity within a company may be determined from a certain set 
of quantitative and qualitative criteria. The quantitative criteria includes share of R&D 
expenditures in the total expenditures of the organization, the share of innovative products in the 
volume of products produced by the organization, number of patents company receives each 
year. The qualitative criteria characterizing the level of innovative activity may include 
prevalence in the organization of technological innovations (product or process) regarding 
organizational and marketing innovations. The choice, which measure to choose, depends on 
industry. 
In pharmaceutical industry, the level of innovativeness may play a crucial role 
strategically. Innovative medicinal products or technologies are new drugs, dosage forms or 
means of delivery of active substances. These innovations may improve or even radically change 
the prognosis of many diseases, modify their course, reduce lethality, and significantly reduce 
the costs of the state for treatment and rehabilitation of patients, and extend the working age. 
This development creates enormous value for customer and skyrocket revenue of producing 
company. Especially in European market (EU), were many big players occupy the industry, the 
development of innovative products and new production processes may elevate the revenue and 
profit of one player and critically decrease these indicators for another. If we look at the 
pharmaceutical market - the main factor that projected to drive the growth is R&D expenditure 
that finally will turn into new products, services and methods of production. 
It may be concluded that two main factors that can be interpreted as a measure of 
innovativeness in pharmaceutical industry are R&D expenditure and number of patents 
companies receive each year. These two metrics represent how the level of innovativeness is 
measured in this paper. 
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At the same time, the way company operates and which strategy follows highly depends 
on top management decisions, especially on Chief Executive Officer’s (CEO’s) decisions. CEOs 
are essential for driving innovation being the central element and the main driving force of any 
innovation process by affecting all stages of innovative management, development of innovative 
ideas and controlling the process of implementation of innovations. The relationship of CEO 
characteristics on R&D activity and number of patents in pharmaceutical industry is 
examined in this paper. CEO’s characteristics such as age, degree and field of education, tenure, 
level of compensation and network may affect the R&D and patenting activity and all these 
factors will be analyzed. Previously, no researches of relationship between CEOs characteristics 
and company innovativeness in pharmaceutical industry in European Union were conducted. 
The main research goal of this paper is to identify the relationship between CEO 
characteristics and innovativeness of the public pharmaceutical companies in European Union 
measured by R&D expenditures and number of new patents obtained. 
The research question to be answered is: which CEO characteristics matter in 
increasing of innovativeness of a pharmaceutical firm and in what extent each of them matters. 
In particular, it is supposed to be determined that some of characteristics such as CEO age, 
educational level and field, tenure, remuneration, hiring from inside or outside and network does 
matter. 
The research objectives are as follows: 
 To conduct a literature review of research papers on the topic of innovations 
and, in particular, analysis of CEO characteristics and their relationship with 
innovations. 
 To study the specifics of innovations measurement in pharmaceutical industry. 
 To conduct an empirical study of determined CEO characteristics that may 
potentially have relationship with innovativeness of pharmaceutical company. 
 To discuss the results of empirical study and develop theoretical and practical 
implications for results. 
The methodology of the study is econometric modeling and regression models 
construction. The dependent variables are characteristics of company innovativeness, such as 
R&D expenditures and number of new patents received. Independent variables are 
characteristics of CEO of public pharmaceutical companies in EU. Three models are constructed 
to determine the relationships of CEO characteristics on company innovativeness: model for 
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R&D expenditures without time lag, model for number of new patents received with time lag 2 
and model for new patents received with time lag 3. 
In this thesis, theoretical and practical contributions are made. The new evidence 
about the correlation between the characteristics of CEO and the level of company’s 
innovativeness in pharmaceutical industry in EU considered to bring theoretical value. Results 
obtained are formed in a form of practical guidelines that are expected to help companies to 
choose the best CEO based on factors that can predict the level of CEO’s innovation orientation. 
The research paper comprises an introduction, two chapters that include the analysis of 
theoretical background regarding research topic, statement and description of research 
methodology, empirical results, findings and discussion, theoretical and managerial implications 
of results obtained, conclusions, and limitations of the conducted research. 
The first chapter starts from giving the definition of innovations and stating that there 
are various approaches to understand the innovations meaning. After that, the role of innovations 
in pharmaceutical industry is disclosed and discussed in order to understand the role of 
innovations in development of companies in this industry. This part is follows by discussing the 
ways of how innovations can be measured in order to choose the way of their measurement for 
this research. Further, the role of CEO in company management is discussed as well as the CEO 
role on innovations is described. The final part of the first chapter dedicated to the possible 
relationship of CEO’s characteristics on firm innovativeness in pharmaceutical industry based on 
existing research papers. On this basis seven hypotheses have been formulated. 
The second part is dedicated to the conducted empirical study. In the beginning of this 
chapter the description of methodology is given: three models are stated and the method of panel 
data analysis is chosen. After this the descriptive analysis of dependent, independent and control 
variables is given. This part is followed by analysis of empirical results that were obtained after 
conduction of regression analysis. Based on these results stated hypotheses were analyzed. 
Finally, the chapter ends with the discussion of the findings and analysis of possible managerial 
implications and limitations of research. 
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Chapter 1. Innovations and the role of CEO 
1.1 The role of innovations and innovativeness measurement 
Definition of innovations 
Nowadays, the term “innovation” included everywhere: in company vision, mission, 
development plan and its objectives. In addition, it is not a rare case to see the position of Chief 
Innovation Officer (CIO) in the board members list in public companies. This pervasiveness of 
“innovation” term has resulted in being named one of the most overused word worldwide 
[O’Bryan, 2013]. But also such frequent use of this term resulted in fact that there is a prevalent 
misunderstanding what does “innovation” means. It leads to incorrect decision making and 
objective setting within firms and individuals and may explain fact that a lot of individuals find 
the innovation elusive [Kuratko, Covin, Hornsby, 2014]. 
The main misbelief is that innovation means something radically new in nature and 
minor changes in existing product does not count. In fact, a radical innovation is very 
challenging and complicated, usually require special resources, and bounded with a substantial 
risk that is much higher than in case of incremental innovation. Incremental innovation means 
smaller changes and balances the innovation process but still it is an innovation. Successful firms 
understand that different kind of innovation, starting from minor incremental innovations to 
major radical ones, play a huge role and tries to develop both. 
The term innovation may be defined in the several ways. Various authors define it as a 
process: Baregheh, Rowleysays that it is a “multi-stage process whereby organizations transform 
ideas into new/improved products, service or processes, in order to advance, compete and 
differentiate themselves successfully in their marketplace”, Bessant, Lamming, Noke argue that 
“innovation represents the core renewal process in any organization. Unless it changes what it 
offers the world and the ways in which it creates and delivers those offerings it risks its survival 
and growth prospects”, Bledow says that it is «the development and intentional introduction of 
new and useful ideas by individuals, teams, and organizations” [Baregheh, Rowley, &Sambrook, 
2009; Bessant, Lamming, Noke, & Phillips, 2005; Bledow, et al., 2009]. Another look at 
innovation as on the outcome: Hobday argue that innovation is “a product, process or service 
new to the firm, not only new to the world or marketplace.”, Kumar highlights that it is “a viable 
offering that is new to a specific context and time, creating user and provider value” [Hobday, 
2005 Kumar, 2013]. Thus, it can be concluded that two common definitions are “the introduction 
of something new” and “a new idea, method, or device”. Although they seem similar, there are 
some important distinctions but at the same time, both approaches are correct. 
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Thus, it is important to understand innovation as both an outcome and process and this 
understanding is crucial for organizations. By focusing on the outcome companies may face 
inefficiencies in innovation development process such as resource overconsumption. By focusing 
on process company may face bureaucracies that make it too difficult to achieve the results 
needed. Thus, view on innovations should be balanced: both processes and outcome 
determination are important. Both innovations as an outcome and innovations as a process 
include various types of innovation depending on area where the innovation was made. 
Innovation as an outcome typically linked with new products and services introduction. 
However, these two examples are only a part of possible innovations as an outcome. In fact, 
innovations as an outcome include product, process, marketing, business model, supply chain 
and other innovations. Description of all innovations as an outcome is as follows: 
 Product innovation means offering of a new products, programs or services. 
Product innovation can include cost reductions, improvement in existing products, 
extension of a product line and other. All these innovations are based on objective to 
increase profits by increasing in market share, product usage of both and strategies that 
companies use may be divided into four types: market penetration, product 
development, market development and diversification. In fact, the majority of 
organizations do not to focus on the only one type of product innovation. On the 
contrary, various types of new product projects have to be considered in one time to be 
able to assemble a new product portfolio that maximizes return [Cooper, Edgett, 
Kleinschmidt, 2002]. Product innovations are mostly about effectiveness. 
 Process innovation aims to change the methodology or process to increase 
efficiency of processes within an organization by lowering costs, fastening production, 
increasing throughput. Process innovation is about efficiency. At the same time, by 
focusing strictly on process innovations ability for product innovations may be limited, 
because product innovations usually requires increase in costs, while process 
innovations aims to decrease them. 
 Marketing innovation includes development of new methods of connection 
company with a customers and consumers. Usually marketing innovation is presented in 
a form of new promotional efforts to increase awareness and brand recognition. 
 Business model innovation changes the industry. IBM in 2009 highlighted three 
types of business model innovation: industry model innovation that includes the 
evolution of value chain by expanding into new industries, revenue model innovation 
that increase revenue by offering of a new product or service mix and enterprise model 
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innovation that innovates the role played by enterprise and networks with vendors, 
customers, employees and other parties. 
 Supply chain innovation is a change in supply technologies, business processes 
and network. These changes may be incremental and radical as well and can lead to the 
new value creation for stakeholders. 
Innovations as a process refer to the way in which innovation should be arranged so that 
the outcomes will finally lead to fruition. In 2015 Product Development & Management 
Association published the process model for innovation by highlighting three phases: 
discovering, developing and delivering. Description of all these phases are as follows: 
 The delivering phase is an essential clarification of innovation. The idea behind is 
that innovative product creation is not the end, execution that means getting this newly 
created offering into the hands of consumers and achieving market acceptance is highly  
important. 
 The process of new product development refers to crucial steps in development, 
milestones setting. Development process include idea generation, its evaluation, 
business case development, preparation phase, technical development and testing. 
 Discovering refers to the market analysis, current products comparison, landscape 
scanning and identification of the potential opportunities. 
It is highly important to all organizations to understand innovations both as a process 
and as an outcome, because it is a requisite for longevity. Innovation leads to expanding of 
productive activities that, in turn, leads to economic growth. Innovations are everywhere. Data 
show that the share of innovative activities worldwide is exponentially growing and reach 2.4% 
of GDP worldwide [OECD, 2015].  
 
1.1.1 Innovations in pharmaceutical industry 
Pharmaceutical industry is driven by innovations. Deep understanding of the market 
needs is necessary, but still insufficient for determination of a firm success. Even if finding of 
effective drugs is vitally important for the millions of patients, 10-20 years of painstaking 
research can still give not a satisfactory result [Gilbert, Henske 2003]. 
The process of new product development takes a long time. This is the reason why in 
the majority of cases each company spends enormous amounts of money to R&D; no other 
industry is under such huge pressure to innovate. In terms of business, the positive momentum 
created by triumphant innovation can have a colossal, lasting for decades effect on the whole 
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pharmaceutical industry. Pharmaceutical companies are in the list of the top investors in R&D 
worldwide [European Commission Joint Research Centre, 2015]. 
Some analysts claims that pharmaceutical R&D accounts for 15 % share of all R&D 
expenditures worldwide - enormous amount for a single industry (figure 1) [Statista database, 
2018].This R&D-based industry spends annually more than $100 billion on R&D, where main 
players, such as Novartis and Roche, spends $10–12 billion annually [IFPMA, 2016]. High 
attrition rates along with the long development times lead to the high R&D costs per new 
product, ranging from $1.24 billion to $1.32 billion and could even be higher if adjusted for 
other cost or inflation [Kaitin, K.I., 2010]. 
 
Figure 1 R&D intensity, by sector, 2016. 
Source: Statista 
Such high R&D costs could be justified. Every company is trying to find a “window of 
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hallmark. Although these scientific discoveries are may create an outstanding competitive 
advantage over others, pharmaceutical companies often are consolidated via M&A, develop 
partnerships with various entities, outsourced information technology, back-office and R&D 
departments.  
Modern medications can affect the quality and the duration of our life in ways, we 
couldn’t imagine even a few decades ago. Some scientists even predict that the average length of 
life will be expanded by 10-20 years in the near future – this could be possible because of 
incredibly fast development of medicine. Over the last 20 years drugs have successfully 
improved the wellbeing of arthritis and Alzheimer’s sufferers all around the Globe, decreased 
number of deaths from heart disease, may treat several types of cancer, and even HIV/AIDS 
[Khulji, Mroczkowski, 2006]. 
The number of deaths from cardiovascular disease has dropped by more than 28 % 
between 1997 and 2007. Innovations development also increased the effectiveness of medicines 
for stroke prevention, arrhythmia, sclerosis, and a lot of other diseases. Promising new drug 
introductions is a main source of competitive advantage for the companies in pharmaceutical 
industry. Moreover, the market is growing and it already reached $1.1 trillion in 2016. The USA 
is the largest pharmaceutical market, while European market is the second [Statista, 2018]. 
 
Figure 2 Distribution of global market revenue from 2010 to 2016, by region. 
Source: Statista 
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As we can see from the data above the share of European market worldwide has a 
downward trend that means that to increase the share there should be made a lot of effort to 
accelerate the research activity in this market. If we look at the pharmaceutical market - the main 
factor that projected to drive the growth is R&D expenditure that finally will turn into new 
products, services and methods of production: by 2022, products that are currently in R&D stage 
will account for 13% of sales in Europe [Statista, 2018]. 
 
Figure 3 European pharmaceutical market, EUR billions. 
Source: Statista 
The effect of a new medicine launch often goes beyond the huge profits achieved that 
could take place especially due to patent protection and first-mover advantage. Incremental, 
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other categories of patients, for example, those who may benefit from other dosage protocols 
[Gupta, Kesarla 2013]. It may sound astoundingly: more than 50% of the new medicines 
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To carry out R&D, manufacturing and marketing of new drugs, thousands of new jobs should be 
created [Selim, 2015]. This fact emphasizes the role of innovation in pharmaceutical industry as 
a powerful mechanism for economic progress. 
At the same time, the development of a new medicine is not an orderly and predictable 
process. Despite the latest achievements in science and technology, the chance still plays a role 
in the discovery of effective compounds. Moreover, there is no way to ensure that years of 
intense, enormous R&D efforts and investment will pay off in the end. 
The success rates in drug discovery remain extremely low. Furthermore, the market 
approval for a new drug depends on governmental agencies that are responsible for regulation 
and control of pharmaceutical industry in each country of region. Players on the market are 
motivated for profit increase and market share, while governments aim for national-wide 
development, social welfare, and technological advances [Bruun, Bennett, 2002]. These specifics 
together make the development and a life cycle of medicines completely different from any other 
technology-intensive industry. 
Medicine innovation emerges at the age of state-of-the-art discoveries covered 
completely different sciences, such as engineering, IT, and biology. Using latest discoveries in 
these and other disciplines, this knowledge should be intersected in a way to create medicine for 
human health and life expectancy improvement. Inventing new medicines is eventually comprise 
an effective business process with a strict fiscal discipline and well-planned and justified 
strategic, organizational, and managerial decisions. 
The European market nowadays faces a cost-containment policies implementation even 
while they attempt to develop the innovative products. The increasing from year to year number 
of Health Technology Assessment agencies and the various changes in pricing and 
reimbursement (P&R) procedures show that innovative drugs have been targeted by cost-
containment policies as well. This is done in order to compete on the market effectively. In some 
cases, company develops product in alliance with other pharmaceutical companies and even on 
the country-level there are alliances. Also, countries combine their strength and knowledge to 
negotiate jointly on prices for newly developed and developing products. Ireland is going to 
unite with Austria, Belgium and Netherlands to boost their collective bargaining. Similar 
tendencies could be seen the Nordic countries, the Balkans, and in central and eastern Europe. 
All these actions aim to accelerate and facilitate innovations development in Europe. 
Nowadays EU pursues two main objectives in its policy on drugs and other 
pharmaceutical products that should secure a high level of public health and innovation and 
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support high level of competition on the market to ensure that Europe continues to receive 
benefit from newly developed medicines. The first objective of policy requires that drugs and 
treatments should be affordable for people and that the quality of medicines should be high. Also 
the patients in EU should receive all necessary information timely, to be informed about various 
ways of treatment. The second objective of policy requires increase the competitiveness of 
European’s pharmaceutical products. All these objectives are tied with innovations development. 
Different sides of pharmaceutical innovation have been the object of analysis in various 
fields such as economics and marketing. However a majority of obtained findings have remained 
somewhat scattered, limited to the particular discipline in spite of broad applicability and 
importance. There are many sides of innovation creation that require further analysis. This is 
why each additional research may have a great relationship on this area, including, for example 
comprehensive overview of the business processes in innovation management or strategic 
planning. Furthermore, one of the biggest questions is how to measure the innovativeness of the 
company. 
 
1.1.2 Approaches to measure the firm innovativeness 
A lot of researchers and practitioners within various industries have studied the ways to 
measure innovation activity. This aim to measure company innovativeness from different sides 
may be explained by a few reasons. First, discovering how to measure innovations can assist 
firms in industries to understand their current innovations capabilities and opportunities and may 
help to find area of focusing to maximize innovation success. In addition, this understanding will 
help to identify strengths and weaknesses and break the barriers that stifle creativity and 
innovations. Benchmark indexes may also be developed based on the most innovative companies 
that may enforce innovation processes in less successful organizations. 
In order to find how to measure innovations, it is important to choose and understand 
the definition of it. Innovation is “the introduction of a new product, service of process through a 
certain business model into the marketplace either by utilization of by commercialization” 
[Gamal, 2011]. Hence, the word innovation could mean completely different things: a new 
product, service, process and business model, but at the same time all these meanings contribute 
to the strengthening of competitive advance of certain firm. Such a broad definition proves the 
fact that innovation is a complex activity that cannot be measure with one simple indicator and 
the way of measurement may depend on industry and understanding of innovations meaning.  
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There are two different streams of innovation measurement. One stream measures 
innovation input, such as R&D expenditure, another measures innovation output, such as number 
of patents and citations. 
 
R&D expenditures 
While competition in all industries is growing from day to day, many companies should 
look for new ways of growing, and for some industries, in particular for the pharmaceutical 
industry, investments in R&D sound be significant [Balkin, Markman, & Gomez-Mejia, 2000]. 
That may enable firms to develop new products, processes and create a future competitive 
advantage [Barker & Mueller, 2002]. 
At the same time, R&D is closely related to the great uncertainty and complex tasks and 
for these reasons requires substantial resources, including information and market knowledge, 
technology, experienced human resources, and colossal financial capital [Chen & Hsu, 2009]. 
Moreover, the data on R&D availability, specifically in pharmaceutical industry, means that 
there is significant evidence on the relationship of  R&D expenditures with companies’ 
innovation input and, consequently, output. 
R&D investment is the primary source of innovation development because it enable 
companies to create demanded capabilities [Balkin, 2000; Dalziel,2011]. Pharmaceutical 
companies are expected to grow in the next years mainly due to introduction of new medicines 
and thus, firms need to have sustained R&D spending and invest financial resources wisely. On 
contrary, a lack of R&D expenditure may prevent a company from being competitive [Kim et 
al., 2009] and may lead to time compression diseconomies that inhibit ability of a company to 
gain a dominating position over competitors due to early investments in innovation creation 
[Kor, 2006]. Because of the nature of pharmaceutical firms and benefits of R&D investment in 
promising area, fast responses are important for other players to increase their innovative 
capabilities. 
R&D projects are complex and place considerable demand on various resources. Some 
authors suggests that maintaining a continuous volume of R&D expenditure is a driver for a 
company [O'Brien, 2003]. Significant resources are needed to ensure the uninterrupted R&D 
activity that, in turn, enhances innovative capabilities [Wincent, Anokhin2010]. 
However, some authors argue that R&D expenditure is not correspond to innovations. 
The reasoning behind is that not all innovative activities are really created in laboratories with a 
help of highly qualified researchers. Measures of R&D are relevant factor to measure 
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professional R&D activity, but sometimes there is an “informal” R&D that is proved to be 
negatively correlated with the technological complexity in company. In this case R&D may 
underestimate the innovation input for many companies [Fieler, 2011]. But this is true for SMEs 
and some not knowledge intensive industries, but not for pharmaceutical that is the reason why 
in this industry R&D may be a relevant indicator. 
Due to importance of R&D expenditures in innovation activity, a majority of researches 
measure innovativeness with a use of indicators that are based on R&D expenditure. For 
example, JoonMo Ahn, Tim Minshall  and LetiziaMortara in their research analyzed correlation 
between CEO characteristics and open innovation adoption and have measures innovations as 
R&D intensity of firm [Mo Ahn, Minshall 2017]. The same pattern could be seen in various 
other papers, because R&D data is available for many public companies [Gonzalez-Uribe 2017; 
Chen 2014]. At the same time, researchers use various indicators for measuring the R&D 
intensity. Some used the ratio of R&D expenditure to net sales [Hsien-Chang Kuo, Lie-Huey 
Wang 2017; Sam Yul Cho, Sang Kyun Kim, 2017] and others used the ratio of R&D expenditure 
to total assets [Hsien-Chang Kuo, Lie-Huey Wang 2017].  
 
Patents 
Using patent system, that includes legal registration in governmental agencies, company 
is able to protect its inventions. Patent obtaining gives many advantages for patentee, where the 
main one is protection from coping, manufacturing or selling and innovative product or service 
without patentee approval. If patents are properly processed, classified and organized, it is a 
great source of valuable information on innovations in industry. Over the last century, innovation 
metrics have included a number of patents as an output measure. Nevertheless, like any other 
factor, patents have strengths and weaknesses as a measure of innovations and these sides were 
analyzed by various researchers. 
Undoubtedly, patent is a direct outcome of years of hard working and research and 
usually company obtain a patent if it is seen that invention should bring a great commercial 
impact [Mansfield, 1986; Sichelman, T., 2011]. Especially, it is an indicator for capturing the 
competitive dimension of innovation change. The process of patent obtaining is time consuming 
and costly that means that company will apply for it if the benefits are expected to overweight all 
costs and in case of pharmaceutical companies, this is often the case. The main advantage of 
patent obtaining is that by doing this you prevent any coping, manufacturing or selling your 
invented product or processes [Narin, F., 1987]. In pharmaceutical industry especially due to the 
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fact that R&D takes a lot of time and resources all inventions are usually patented. Moreover, 
some companies sell the license like any other asset, in order to get an additional stream of 
revenue for the business. 
However, the truth is that many valuable innovations may still not be protected by a 
patent or even be patentable [OECD, 2009]. It is a fact that patents may vary in terms of their 
value and importance and there is a belief that there are patents that are not able to capture 
innovative output [Hu and Mathews, 2005]. Some researchers propose to use a patent citation 
rates as a measure of innovativeness. The idea behind is that citations may highlight the 
importance of an invention [Jaffe, 2001; Alcacer, 2006].At the same time, this creates a 
truncation issue that arises from the difference between old and new patents citations [Hu and 
Mathews, 2005]. 
Another alternative is a renewal fees that mean the total costs and time period for which 
the company pays renewal fees in order to maintain the legal value of the patent. Also, not all 
results of scientific research have to be protected by a patent in order to reach the industry. 
Nevertheless, various empirical studies suggest that a huge share of companies' innovations are 
patented. To be exact, companies usually apply for a patent in 65-85% of cases where a patent 
may be obtained. We can conclude that firms make use of patenting for the majority of their 
patentable inventions that is in particular true for pharmaceutical companies. 
It is fact that patents have a greatest value in chemical and pharmaceutical companies 
where the cost of imitation is greatly less than the initial investments in R&D [Arundel and 
Kabla, 1998]. This means that number of patents is significant for company development and 
patenting activity fairly can be named one of the most important measures of the success of 
invention.  
 
1.2 CEO characteristics and innovations  
The role of CEO in company management 
Over the past few decades, the issues of companies’ management have been actively 
analyzed. It this researches an important place is devoted to studying the relationship of the 
company's top management and its financial performance and other important indicators. One 
group of scientists argues that the actions of the manager are considerably limited by the 
institutional features of the company's functioning, for example, its inertness, dependence on the 
chosen development strategy and the availability of a certain set of resources. Due to this fact it 
is argued that top managers are not able to have a significant influence on the firm's activities 
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[Hannan, Freeman, 1977; DiMaggio, Powell, 1983; Haveman, 1993]. In other works, it is stated 
that the head of the company is seen as a strategic resource and along with other resources has a 
significant impact on the company's performance. 
One of the fundamental researches in the field of studying the influence of top managers 
on firms' activities says that demographic and professional characteristics of managers can be 
considered as proxy variables for their managerial capabilities, the impact of which is reflected 
in the financial performance of companies [Hambrick, Mason, 1984]. This approach was called 
“The Upper Echelon Theory”. The main idea of this theory is based on the following 
assumptions. First, leaders assess the situation and make strategically important decisions based 
on their personal vision of the problem, which is formed through experience, values and personal 
characteristics. In turn, these decisions affect the company's operations in general, and as a 
result, its financial performance. Secondly, it is almost impossible to obtain psychometric 
information about the top managers of companies, so scientists agreed that demographic and 
professional characteristics (age, education, work experience, etc.) can reflect managerial skills 
and abilities. As practice showed, this point of view is held by a fairly large group of scientists 
[Carpenter, Geletkanycz, Sanders, 2004; Mackey, 2008]. 
 
CEO characteristics and innovations 
Many research papers on organizational innovations emphasize that a huge role in 
innovations development play staff, management and technical experts. Thus, the characteristics 
of employees and management of a firm have an impact on strategic decisions and critical for 
people who champion innovations. Champions are people who in fact emerge to promote an 
innovation activity within organizations because they have an expertise, required resources and 
other important characteristics to affect the innovation development. It is believed that the role of 
top management is to influence differently on strategic innovations. It is true that strategic 
decisions and innovations within the companies are adopted and championed via influence from 
inside or outside. Thus, the role of top management, and in particular CEO, cannot be 
underestimated: they are the key actors and champions in the strategic innovation development 
and are responsible for implementation and development of innovations. 
Executives are able to allocate resources, provide vision, structure, guidance and other 
in order to enhance and speed up innovation development and adoption. At the same time, 
champions differ from firm to firm. They have different values, leadership style and use a variety 
of instruments to make an impact. Partly, it is due to some external factors such as culture, but 
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mostly they differ due to differences in personal treats. Moreover, leadership style and 
instruments to have an impact champions are likely to differ for each major type of innovation. 
For instance, product innovations usually benefit more from external factors such as information 
and marketing expertise, while the process innovations are influenced more by organizational 
information and internal expertise, but some characteristics of management should be common 
for all innovation types. 
If we look at innovation management from the upper-echelons perspective, CEOs are 
acting based on their personal understanding of the strategic goals of a company and situations 
they confront previously. CEOs are the heads and leads of their companies in more ways than 
one. In fact, CEOs have the power, and even an obligation, to set correct strategic direction of a 
company and focus the attention of company employees on particular areas of endeavor. To 
innovate companies should detect the appearance of a new technology and realize some future 
application for it. Detection, development, formation and adaptation require the knowledge about 
existing external opportunities and the apprehension of future events. Due to this fact, CEOs 
attention on events that have not occur yet but may take place and on events that already happen 
outside the company are predictors of firms’ innovativeness. 
When CEOs looks in the future and on external organizations, their actions inevitably 
will reflect this overall strategic focus. CEOs will drive employees’ attention to these changes 
and issues. In turn, this should lead to fastening the detection by the company of new 
technological opportunities and innovations. A greater attention to possible events that may have 
an impact of company functioning also leads to greater mobility and preparedness for these 
events in the future, enabling faster and more effective development and deployment of 
innovations. 
Many researchers have studied CEO characteristics as a significant factor that 
determines firm performance, because CEOs have different previous experience, tenure, 
education, skills, knowledge and business judgment. However, previous studies have revealed 
conflicting results [Lefebvre, Lefebvre 1992; Lefebvre et al. 1997; Papadakis; Khurana 2002; 
Yadav et al. 2007]. 
Some researchers have stated that CEOs overall have a positive relationship with firm’s 
financial performance and innovations, whereas others suggests that CEOs tend to miss 
disruptive technologies due to the fact that they tend to focus on daily business activities, but not 
on innovation development, the results of which are unclear [Yadav et al. 2007]. At the same 
time, taking into account these conflicting results, the literature confirms that CEO has a strong 
effect on firm innovativeness [Papadakis and Bourantas 1998; Yadav et al. 2007]. 
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1.3 CEO characteristics and firm innovativeness in pharmaceutical industry: hypotheses 
statement 
Interest for innovative development in pharmaceutical industry shows that technology, 
product and process innovations and fast adaptation to changing environment are crucial factors 
of companies’ success. Research papers on pharmaceutical innovation from managerial and 
organizational points of view highlight a close relationship between extend and speed of 
technological change and strategy of a company. 
In fact, process of innovations development in company is a mix of social, organization, 
political, economic and management factors. In this list of factors the role of management and, in 
particular, CEO cannot be underestimated. The choice of management team and CEO may 
radically change the way company operates, its values, goals and short-term, long-term 
objectives. 
 Company that wants to innovate requires a champion: the strong leader who will 
understand the value and importance of innovations push forward organizational level changes 
and extend the benefits inside companies [Smith, 2007]. Even though companies may not 
withstand technological development, they may withstand the changes involved [Schein, 1985]. 
For all companies in pharmaceutical industry it is important to know CEO with which 
characteristics innovate more. Thus, it this research paper a list of hypotheses was stated.  
The first hypothesis is related with the age of CEO. The older CEO becomes, the more 
knowledge and skills he or she acquires due to gained experience and trainings. Undoubtedly, 
this experience is valuable to the company and the older CEO becomes, the more efficient he or 
she could be in solving daily tasks. Nevertheless, older managers not only tend to have less 
physical and mental stamina [Child, 1974], but also have less ability to discover new ideas, 
methods of their application and new behaviors. These actions are linked with ability to innovate 
and think creatively. Also, the older CEO becomes, the more information he or she seeks before 
making decision and the longer it takes to make decisions, whereas young CEO have greater 
abilities and determination in making decisions faster and with confidence [Taylor, 1975]. 
Different researches have analyzed the role of CEO age. Reinganum found that an older 
CEO usually not interested in investing into new product development despite of it succeeds is 
strengthening its market position [Reinganum, 1983]. Marshall also found that the CEO age is 
important for innovations development: the older he or she is, the more he or she rely on their 
own information sources when they make decisions, and less likely to take risks [Marchall, 
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2006]. Jovanovic argues that older CEOs usually less dependent on external conditions and rely 
on their own knowledge and fields of expertise [Jovanovic, 2001]. Barker & Muller also have 
analyzed the relationship between CEO characteristics and innovativeness that is measured by 
R&D expenditures and argued that CEOs who is younger is positively correlated with R&D 
investment [Barker & Muller 2002]. Similar results were obtained by some other researchers 
[Yan Yong-hai, 2010]. 
Moreover, for older managers, it is very important to be financially secured and to have 
clear career path. Hence, older CEOs may avoid risky actions that could undermine this security. 
On contrary, younger CEOs tend to be less risk-averse. Thus, the younger CEO is, the more 
likely he or she will pursue innovative and risky strategies. Companies where CEOs are young 
are able to go through the risky changes and actions needed to succeed in unstable and changing 
environment. 
Due to these facts, firms with younger CEOs will probably have higher growth and 
variability in profitability in comparison with industry averages, relative to firms with older 
CEOs. Moreover, because risk is linked with innovations, it could be expected that firms with 
younger CEO will be more innovative in terms of number of new patents and R&D spending. 
Thus, it is expected that the younger CEO in pharmaceutical industry is, the more innovative 
company is: R&D expenditures are higher and number of patents is more than in company where 
CEO is older. Thus, the first hypothesis was formulated: 
H1. CEO age negatively relates to the company innovativeness. 
 
 A CEOs’ educational level: whether he or she has received bachelor’s, master’s or 
doctoral degree influences on strategy planning skills and also contributes to the readiness and 
openness of firm to change [Classen et al., 2012]. At high level, the higher degree of education 
is, the higher is the ability to identify and apply an external knowledge that are essential for 
absorptive ability and capacity [Roach and Sauermann, 2010]. Using developed through 
education analytical skills and strong information processing ability CEOs who received 
master’s and PhD are able to weight a lot of information simultaneously. Because innovations 
development is complex process, a CEO who can faster process a lot if information flows will 
enable a company to detect and manage the knowledge that will in turn increase the strong 
absorptive capacity and establish an atmosphere for innovations development. 
Lin et al have analyzed the relationship between CEO characteristics and innovativeness 
that is measured by R&D expenditures. Their results supported the statement that CEO 
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educational level is positively related to firm innovation efforts [Lin et al, 2009]. Wen Fang et al 
claim that educational level of CEO has significant and positive relationship with R&D spending 
[Wen Fang et al 2009]. 
Also, CEOs who acquired wide set of knowledge and has developed skills during their 
studies inevitably becomes more knowledgeable on innovation, or in processes that can be useful 
for innovation development. Highly educated CEOs are in favor of innovation and are able to 
give relevant advice on decisions. Some researchers claim that the advanced master’s and PhD 
level of CEOs education improves their assessment of the firm’s R&D activities. CEOs with 
such background have knowledge on innovation management and thus are able to advise and 
manage successfully an innovation processes in company. Apart from this, directors with 
master’s and PhD educational levels usually are aware of new technologies and trends, which is 
useful for innovation management [Lin, Lin, Song, & Li, 2011].It may be suggested that 
master’s and doctoral degree corresponds to higher innovativeness than if CEO received only 
bachelor degree. The second hypotheses can be formulated. 
H2. Innovativeness of companies where CEO has received master’s or doctoral degree is higher 
than innovativeness of companies where CEO did not receive such degrees. 
 
Companies that want to innovate and adapt approaches for innovative development 
through better understanding and absorbing information may consider appointing CEOs with 
engineering or medical educational background. Some researchers claim that directors’ technical 
skills and knowledge is positively related to R&D costs [Dalziel et al. 2011]. Pharmaceutical 
firms may want to appoint directors with an engineering background, because such CEOs are 
usually in trend with recently introduced technology, needs of consumer, supplier capabilities 
and governmental regulations [Chen, 2014]. Thus, they have a better insight into emerging 
opportunities and are able to adapt them faster. CEOs with knowledge and experience in medical 
research may also be demanded since innovations in pharmacy require specific knowledge of 
industry and products. That is especially important when it is product innovation: improvements 
in recipes, components, or new treatment method.  
On contrary, CEO’s economic expertise is undoubtedly valuable for the company overall: 
is leads to effective planning and controlling processes in a vast scope of fields. They have a 
deep understanding of all procedures within a company, accurately develop budgets, and control 
financial reports. However, a CEO’s economic background usually leads to cost cutting that may 
be less favorable for innovative projects, that requires considerable investments and assumed to 
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be highly risky. Some researchers claim that the CEO’s economic expertise is negatively linked 
to opportunities for growth [Jeanjean, Stolowy 2009]. Education in economics leads to 
bureaucratic policies appearance, and paying the highest attention to financial reporting instead 
of developing and adaptation of innovations [Naranjo Gil, Mass, 2009].Thus, it may be expected 
that if CEO has an education in engineering or medicine innovativeness of company will be 
higher than in company where CEO has an education in other field. 
H3. Innovativeness of companies where CEO has received education in medical or engineering 
field is higher than innovativeness of companies where CEO is not educated in these fields. 
 
The knowledge that CEO receives due to personal working experience undoubtedly 
affects the way he or she select and implement strategies. For CEOs who have a deep business 
expertise and experience, it is much easier and faster to learn about how a company operates 
which strategy follows and what is done incorrectly. All these factors CEOs take into account 
when making significant decisions. All gained knowledge and experience enable CEOs to make 
judgments and offer rational and constructive criticism. Gained professional experience inside or 
outside the company CEO operates will help to acquire necessary skills that cannot be entirely 
covered and gained through education. Such findings are supported by some researches [Grazzi 
M., D. Moschella, 2017]. 
At the same time, some scientist found that tenure has a negative relationship with 
company’s innovativeness [Lefebvre, 1992]. Zajac and Stearns also claim that CEO tenure has 
significant negative relationship with R&D expenditures [Zajac & Stearns 1997]. It is explained 
that a longer tenure corresponds to more habit-based decisions, greater reluctance to change 
policies and products, and thus smaller likelihood to do radical changes. 
Tenure may also be linked with company innovativeness: short tenured CEOs, because of 
possible lack of experience in industry or on this particular position may not be able to 
effectively assess strategic risks and opportunity to innovate. On contrary, long tenured CEOs 
that have accumulated knowledge of the firm’s environment may become inflexible in 
implementing changes when it is risky or when the outcome in unclear. 
Wen Fang et al claim that professional experience of CEO has significant and positive 
relationship with R&D spending [Wen Fang et al 2009]. Liu YunGuo et al analyzed the effect of 
CEO tenure on R&D. Their results show that R&D expenditure is positively related with CEO 
tenure [Liu YunGuo et al 2007]. Barker and Muller found that CEO tenure is positively 
correlated with R&D spending [Barker & Muller 2002]. 
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Overall, it is expected that the longer tenure is, the more innovative company becomes, because 
CEO may see a field for improvement, access all risk and manage changes effectively. Thus, it 
may be concluded that in pharmaceutical industry professional experience gained as well as 
tenure length are positively related with company innovativeness. 
H4.1 CEO tenure positively relates to the company innovativeness. 
H4.2 CEO industry experience positively relates to the company innovativeness. 
 
In various industries, networks of directors may help enforce contracts and overcome 
market inefficiency. Members of the networks usually share similar backgrounds or experience 
and feel committed to their networks. The networks help to share useful information about trends 
and dynamics in industries: productive resource and knowledge exchanges bring support to 
innovation. When they have wide business knowledge, directors may acquire new skills and 
objectivity [Kesner, 1988]. Business connections contribute to building useful capabilities for 
innovative companies through joint ventures creation and technology transfer 
[Markarian&Parbonetti, 2007]. When information is acquired from CEOs’ is usually considered 
to be more reliable [Lynall, Golden, & Hillman, 2003]. Palmer and Barber claimed that the 
bigger director’s network is, the more probably company will be innovative [Palmer & Barber 
2001]. Directors’ interconnections give a better view of the sustainability of R&D activities 
because various issues are usually the same in other companies and also that they know 
organizations that have already succeeded. In addition, R&D and new patents development 
require considerable investments where CEOs’ network can help find extra financial support, 
access necessary resources, which could compensate company’s limited capabilities. For all 
aforementioned reasons, it may be expected that the size of network of directors positively 
relates to the company innovativeness. 
H5. The size of network of directors and interlocks with various industries positively relates to 
the company innovativeness. 
 
The structure of CEO compensation is constantly evolving and changing and often 
depends on current economic and political situation. Nevertheless, amount of total remuneration 
as well as the usage of various compensation elements follows trends over the time. The base 
salary is a fixed amount that CEO will get regardless of the company financial performance and 
actions that has been done over the period. Thus, the fixed payment should not motivate the CEO 
to act effectively and put the efforts to increase company performance. Respectively, only a part 
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of CEO remuneration is fixed: CEOs usually receives bonuses as payoffs that depend on annual 
firm performance and often measures based on financial results of a company. This means that a 
considerable part of CEO compensation tied with company performance [Lerner and Wulf, 
2007; Francis, Bill & Hasan, 2011]. 
Some may argue that such dependence of performance may motivate the CEO to manage 
earnings in a way to improve it only in short-term instead of long-term value creation. However, 
especially if the CEO contract is not time-limited focusing only on short-term is not rational 
decision. In addition to this, it may be claimed that such payment structure affect the risk-taking 
behavior of CEO in favor of avoiding risky business decisions. Shim et al found strong 
relationship between CEO total compensation and company innovativeness [Shim et al 2009]. 
However, in pharmaceutical industry it is clear that implemented innovations are crucial for 
company long-term development. Thus, CEOs realize the importance of it for company and 
respectively for remuneration. It may be concluded that the fixed part of the salary is unlikely to 
motivate CEO to follow innovation strategy, and is not significant, while total remuneration 
positively relates with company innovativeness. 
H6.1 The size of fixed compensation negatively relates to company innovativeness. 
H6.2 The size of total compensation positively relates to company innovativeness. 
 
In general, there is no excessive performance advantage between CEO that has been 
promoted from inside or from outside — CEOs with both the most outstanding and lowest 
performance may come from each category. However, it could not be said that it do not matter 
whether a company appoint a CEO from the inside or outside. Some studies found that CEOs are 
appointed from inside much more frequently than outsiders when company has a stable financial 
situation, while in challenged companies CEOs are highbred from outside more frequently. At 
the same time, statistic shows that performance of insider is slightly higher that performance of 
outsider. As for innovations, CEO that has been promoted from the position inside may feel 
more committed to the company and know better the field for improvements as well as where to 
innovate. Such positive effect has been found by some researchers [Balsmeier, Buchwald, 2015; 
Giambatista et al., 2005; King & Anderson, 1990]. Thus, in can be expected that innovativeness 
of companies where CEO was promoted from the position inside the company is higher than 
innovativeness of companies where CEO is outsider. 
H7. Innovativeness of companies where CEO was promoted from the position inside the 
company is higher than innovativeness of companies where CEO is outsider. 
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Chapter 2. Empirical study 
2.1 Research methodology 
The research is based on analyzing the information about European public 
pharmaceutical companies. As it has been stated before the main research goal of this paper is to 
analyze how different CEO characteristics are connected with innovativeness of the public 
pharmaceutical companies in European Union.  
The analysis is econometrics modeling. Similar technique has been used in various 
papers that aims to identify the relationship of CEO characteristics and innovative characteristics 
of companies [Hsien-Chang Kuo, Lie-Huey Wang 2017; Allemand I..Brullebaut B., Galia F., 
Zenou E., 2017; Chen, H. L. 2014]. Models have been tested in R studio, an integrated 
development environment for R.  
For this research, secondary data is collected. The information about R&D, revenue is 
gathered from Tomson Reuters Database and annual reports. Information about CEOs is 
collected from annual reports, Bloomberg profiles and companies websites. Data about firm age 
is taken from companies’ websites. 
In this research, the next variables will be used: 
 
Table 1.Description of variables 
 Variable Description 
Independent 
variables 
Age The age of the CEO at the end of a fiscal year. 
Calculated as the observed year minus the year 
of CEO birth 
Master The variable shows if an executive has 
obtained master degree. 
1 – has obtained, 0 – otherwise. 
Doctor The variable shows if an executive has 
obtained doctorate degree. 
1 – has obtained, 0 – otherwise. 
MBA The variable shows if an executive has 
obtained MBA degree. 
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1 – has obtained, 0 – otherwise. 
Med The variable shows if an executive has 
obtained education in 
chemistry/biology/medicine 
1 – has obtained, 0 – otherwise. 
Engineer The variable shows if an executive has 
obtained education in engendering 
1 – has obtained, 0 – otherwise. 
Econom The variable shows if an executive has 
obtained education in economics 
1 – has obtained, 0 – otherwise. 
Experience The variable shows a number of years CEO is 
working in pharmaceutical industry 
Tenure The variable shows a number of years on the 
CEO position in the company at the end of a 
fiscal year rounded. 
Calculated as a number of observable year 
minus year when CEO has been appointed to 
the position 
Insider The variable shows whether CEO was 
appointed from another position within the 
company 
1 – from inside, 0 – from outside. 
Network.dir Number of executive managers with whom 
CEO has been working with 
Calculated as a number of directors with whom 
CEO has been working with 
Network.ind Number of industries where executives from 
CEO network have been working 
Calculated as a number of industries where 
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directors, whom CEO know, are working 
Fixed.comp The amount paid to the CEO on the fixed basis 
in observable year 
Calculated as fixed compensation in observed 
year 
Total.comp The total amount paid to the CEO in 
observable year 
Calculated as total compensation received by 
CEO in observed year 
Variable The share of variable part of a compensation in 
total remuneration 
Calculated as the difference between total CEO 
remuneration and its fixed part divided by total 
amount of remuneration in observed year 
Dependent 
variables 
R.D.Exp The variable shows R&D expenditures in 
observed year 
Calculated as a logarithm of R&D expenditures 
in observed year 
NewPatents The variable shows the number of patents 
received in observable year 
Control variables Firm.age A proxy variable for firm age, calculated as 
observable year minus year of company 
foundation rounded 
Company size Revenue A proxy variable for firm size, based on firm’s 
revenue in the end of the year 
Calculated as a logarithm of Revenue in the 
end of the year 
Source: made by the author 
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Model for R.D.Exp 
Variable R.D.Exp is analyzed by using linear regression without time lag, because the 
CEO characteristics have immediate effect on amount of R&D expenditures. 
𝑦𝑖 = 𝛼 + 𝛽1𝐶𝐸𝑂𝑖 + 𝛽2𝑐𝑜𝑛𝑡𝑟𝑜𝑙_𝑣𝑎𝑟𝑖𝑎𝑏𝑙𝑒𝑖 + 𝜀𝑖 
In this equation 𝑦𝑖, represents the dependent variable R.D.Exp counted for i
th 
observation,  𝛼 is an unknown scalar quantity, the regression intercept, 𝛽1, 𝛽2 – vectors of 
coefficients in a modeled linear regression, 𝐶𝐸𝑂𝑖, 𝑐𝑜𝑛𝑡𝑟𝑜𝑙_𝑣𝑎𝑟𝑖𝑎𝑏𝑙𝑒𝑖 – independent and control 
variables for ith observations, 𝜀𝑖is a random error term that appears due to existence of other 
factors that are not included in the model. 
 
Model for NewPatents 
Variable NewPatents is analyzed by linear regression with 2 and 3 years time lag, 
because the CEO characteristics do not have immediate effect on number of new patents per 
year. For example, in model with time lag = 3, CEO characteristics in 2009 are analyzed to have 
relationship with the number of new patents in 2012. 
𝑦𝑖 = 𝛼 + 𝛽1𝐶𝐸𝑂𝑖−𝑙𝑎𝑔 + 𝛽2𝑐𝑜𝑛𝑡𝑟𝑜𝑙_𝑣𝑎𝑟𝑖𝑎𝑏𝑙𝑒𝑖−𝑙𝑎𝑔 + 𝜀𝑖 
In this equation 𝑦𝑖, represents the dependent variable counted for i
th observation,  𝛼 is an 
unknown scalar quantity, the regression intercept, 𝛽1, 𝛽2 – vectors of coefficients in a modeled 
linear regression, 𝐶𝐸𝑂𝑖−𝑙𝑎𝑔, 𝑐𝑜𝑛𝑡𝑟𝑜𝑙_𝑣𝑎𝑟𝑖𝑎𝑏𝑙𝑒𝑖−𝑙𝑎𝑔 – independent and control variables for i
th 
observations, 𝜀𝑖is a random error term that appears due to existence of other factors that are not 
included in the model. 
 The data gathered is a panel data. This means that for regression analysis a several 
regression modes can be chosen: 
 The pooled model. This model is based on assumption that there are neither unique 
characteristics of individuals within the set, nor universal effects over time. The intercept 
and the slope coefficients are constant across time and objects, and the random error term 
captures these differences over objects and time. 
 The fixed model. Model implies that there are some unique characteristics of individuals 
and they are constant. These characteristics may have an impact on the predictor or 
outcome variables and model aims to control for this. The slope coefficients are constant 
but the intercept varies over objects. 
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 The random effects model. This model is based on the assumption that there are some 
unique, constant over the time characteristics and they are not correlated individual 
repressors. The slope coefficients in this model are constant but intercept varies over 
objects and time. 
To make sure that chosen model is appropriate several tests should be conducted. All 
models were tested on all three regressions. All three models were created using R instruments.  
First, the panel model was build based on initial dataset. Because some cells were 
empty due to lack of data, they were remained from the final dataset. Company number (ID) and 
year of observations (Year) – are indexes based on which the panel model was build. After this, 
all three models were created using R instruments and after test to determine whether one model 
or another is better was conducted: 
 Lagrange Multiplier Test for random effects versus pooled was conducted. The 
result showed that random effects model is better than pooled. 
 F test for individual effects showed that there are significant fixed effects and that 
this model is better that pooled. 
 Hausman Test was used to determine what model is better: with fixed effects or 
with random. Result showed that the model with fixed effects should be used in 
further analysis. 
To sum up, the model with fixed effects should be used in panel data on pharmaceutical 
companies’ analysis. 
 
2.2 Data and sample 
The data is gathered for public pharmaceutical companies registered in European 
Union. The sample includes 55 companies (out of 65 public pharmaceutical companies in EU) 
for which all needed data for the 8 years from 2009 to 2016 was available. 
EU pharmaceutical public companies present different countries, but some of countries 
are leaders in number of public pharmaceutical companies, while other do not have them at all. 
Sample for research includes 55 companies from 19 countries (Figure 4). 
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Figure 4 Map of countries where companies from sample locate. 
Source: made by the author 
The biggest number of public companies are located in United Kingdom, where 13 
pharmaceutical companies are based. The second biggest number of public pharmaceutical 
companies is in France: 8 companies. The third country in the list is Germany, with 7 companies. 
Table 2. List of countries where companies from sample locates 
Number of a country Country Number of public pharmaceutical companies 
1 United Kingdom 13 
2 France 8 
3 Germany 7 
4 Denmark 4 
5 Romania 3 
6 Spain 3 
7 Bulgaria 2 
8 Ireland 2 
9 Italy 2 
10 Sweden 2 
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11 Belgium 1 
12 Croatia 1 
13 Cyprus 1 
14 Finland 1 
15 Hungary 1 
16 Latvia 1 
17 Poland 1 
18 Portugal 1 
19 Slovenia 1 
Source: made by the author 
Some of the companies in sample have been controlled by families for generations: the 
executive board manly consists of members of one family. At the same time, majority of 
companies in sample are not family-owned. The average age of a company in dataset is 61. That 
could be explained that it usually takes long from the moment of company foundation to the 
moment of IPO. 
Before conduction of the regression analysis, aiming to research connections between 
characteristics of CEO and innovativeness of the company, the descriptive analysis was 
performed. 
Table 3.Descriptive statistics of dependent variables 
Dependent 
Variable 
Mean Median St. Deviation Min Max 
R.D.Exp 439904.0000 16512.0000 1144717.00000 2.00000 5450000.0000 
NewPatents 4.5350 0.0000 9.38083 0.00000 77.0000 
Source: made by the author 
Based on the descriptive analysis of dependent variables it can be said that the spread of 
the indicators is very high for R&D expenditures in absolute value, while for new patents, the 
spread is much smaller. As a result, the variables should be analyzed taking into account the size 
of the company as well. 
Descriptive analysis for independent variables descriptive statistics are presented below: 
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Table 4.Descriptive statistics of independent variables 
Independent 
Variable 
Mean Median St. Deviation Min Max 
Age 53.840    54.000    7.056 35.000 72.000 
Master 0.640 1.000 0.481 0.000 1.000 
Doctor 0.321 0.000 0.467 0.000 1.000 
MBA 0.212    0.000 0.409 0.000 1.000 
Med 0.358    0.000 0.480 0.000 1.000 
Engineer 0.151    0.000 0.358 0.000 1.000 
Econom 0.476    0.000 0.500 0.000 1.000 
Experience 24.430 25.000 9.347 1.000 50.000 
Tenure 6.869 5.000 6.385 1.000 48.000 
Insider 0.533   1.000 0.500 0.000 1.000 
Network.dir 18.660 7.500 26.305 0.000 142.000 
Network.ind 4.044 3.000 4.024 0.000 20.000 
Fixed.comp 493.200 308.000 455.412 28.000 3014.000 
Total.comp 1690.000 515.000 3144.029 39.000 26451.000 
Variable 0.453 0.431 0.268 0.007 3.363 
Source: made by the author 
In general, the spread of the indicators is relatively low for majority of variables. An 
exception is high spread for fixed and total compensation. It may be suggested that these 
variables are highly dependent on the size of the company: the bigger company is, the higher 
CEO remuneration may be expected. A vast majority of CEOs are man (96%), 54 years old, in 
64% cases CEO has a master degree, in 32% a doctoral degree, in 21% received MBA. 48% of 
CEOs in the sample received degree in Economics, 36% received degree in medicine, pharmacy 
or related studies, 15% received degree in engineering. In general, CEOs have been working in 
pharmaceutical industry for 24-25 years and occupy the CEO position for 7 years. In 53% CEO 
was hired on this position from inside. The size of network for CEOs vary a lot, but in general 
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the network is 18 directors from 4 various industries. Fixed and total compensations significantly 
differs across all companies in the sample, but the median is 308 fixed, 515 total. 
Based on descriptive statistics above the average portrait of CEO can be created. The 
average CEO in pharmaceutical industry is 54 years old man, has obtained Master degree in 
Economics. Before becoming a CEO he has been working in pharmaceutical industry around 24 
years. He has occupied current CEO position for 7 years after working in current company for 
some time. Most probably, he will be connected with 18 directors across 4 different industries. 
Fixed compensation highly depends on company, but in average (mean) he receives 308 
thousands euro per year. Total compensation includes fixed and variable parts, where variable 
part is 45% of the fixed one. 
For control variables the descriptive statistics are presented below: 
Table 5.Descriptive analysis of control variables 
Control Variables Mean Median St. Deviation Min Max 
Revenue 3567954.000 269871.000 8812403.000 12.000 46670473.000 
Firm.age 65.960 47.000 7.056 1.000 349.000 
Source: made by the author 
As it can be seen, the age of a companies’ vary significantly: from 1 year from 
foundation moment to 349 years. The same can be said about revenue, but in absolute terms it 
vary much more: from 12 to 46 670 473 thousand euros. Thus, both variables may have a 
moderation effect of regressions so that all influence should be checked. 
In order to clarify that variables are do not have any relationship, connection, or 
interdependence between each other the correlation matrix has been analyzed (Table 6).  The 
highest correlation have variables Experience and Age. It could be explained by the fact that 
there are many CEOs who have been working in industry starting from their graduation from 
university. At the same time, correlation as not extremely high: some CEOs come to pharmacy 
from other industries such as consulting. Also, in hypotheses that have been stated different 
effect from variables Experience and Age is expected: negative for age and positive for 
experience. This fact supports the idea that both variables should remain included in the sample.  
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Table 6. Correlation matrix 
 
Year 
New 
Patents 
R.D.exp Age Gender Master Doctor MBA Med Econom Engineer 
Year 1,00 0,10 0,04 0,17 0,00 -0,04 -0,04 0,08 -0,01 0,04 -0,05 
NewPatents 0,10 1,00 0,03 0,18 -0,07 -0,02 -0,01 0,11 0,05 0,00 0,04 
R.D.exp 0,04 0,03 1,00 0,07 -0,07 -0,10 0,02 -0,03 0,00 0,05 -0,11 
Age 0,17 0,18 0,07 1,00 -0,15 0,05 0,05 0,13 0,22 0,03 -0,14 
Gender 0,00 -0,07 -0,07 -0,15 1,00 -0,05 0,07 0,15 0,07 0,01 -0,08 
Master -0,04 -0,02 -0,10 0,05 -0,05 1,00 0,34 -0,08 0,34 -0,31 0,04 
Doctor -0,04 -0,01 0,02 0,05 0,07 0,34 1,00 -0,02 0,17 -0,24 -0,04 
MBA 0,08 0,11 -0,03 0,13 0,15 -0,08 -0,02 1,00 0,22 0,05 0,23 
Med -0,01 0,05 0,00 0,22 0,07 0,34 0,17 0,22 1,00 -0,38 -0,13 
Econom 0,04 0,00 0,05 0,03 0,01 -0,31 -0,24 0,05 -0,38 1,00 -0,30 
Engineer -0,05 0,04 -0,11 -0,14 -0,08 0,04 -0,04 0,23 -0,13 -0,30 1,00 
Experience 0,14 0,22 0,14 0,42 -0,02 -0,14 -0,03 0,00 0,06 -0,01 -0,26 
Tenure 0,08 -0,05 -0,09 0,26 -0,09 0,17 0,17 -0,01 0,04 -0,10 -0,15 
Network.dir -0,05 0,40 0,13 0,05 0,04 -0,07 0,04 0,08 0,19 -0,24 -0,05 
Network.ind -0,02 0,41 0,35 0,09 -0,08 0,05 0,08 0,09 0,14 -0,10 -0,03 
Insider -0,03 0,07 -0,06 -0,05 -0,01 0,00 -0,02 -0,17 -0,13 -0,13 0,03 
Fixed.comp 0,14 0,04 0,61 0,12 -0,09 -0,09 0,08 0,15 0,18 -0,09 -0,07 
Total.comp 0,13 -0,04 0,45 0,10 -0,08 -0,05 0,14 0,15 0,07 -0,04 -0,06 
Variable 0,05 0,12 0,44 0,16 -0,06 -0,11 0,03 0,04 -0,01 0,13 -0,02 
Revenue 0,03 0,07 0,96 0,09 -0,08 -0,09 0,04 -0,05 0,01 0,05 -0,10 
Firm,age 0,03 0,24 0,45 0,21 -0,09 0,00 0,13 -0,03 0,02 0,03 0,00 
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Experience Tenure 
Network. 
dir 
Network. 
ind 
Insider 
Fixed. 
comp 
Total. 
comp 
Variable Revenue 
Firm 
age 
Year 0,14 0,08 -0,05 -0,02 -0,03 0,14 0,13 0,05 0,03 0,03 
NewPatents 0,22 -0,05 0,40 0,41 0,07 0,04 -0,04 0,12 0,07 0,24 
R.D.exp 0,14 -0,09 0,13 0,35 -0,06 0,61 0,45 0,44 0,96 0,45 
Age 0,42 0,26 0,05 0,09 -0,05 0,12 0,10 0,16 0,09 0,21 
Gender -0,02 -0,09 0,04 -0,08 -0,01 -0,09 -0,08 -0,06 -0,08 -0,09 
Master -0,14 0,17 -0,07 0,05 0,00 -0,09 -0,05 -0,11 -0,09 0,00 
Doctor -0,03 0,17 0,04 0,08 -0,02 0,08 0,14 0,03 0,04 0,13 
MBA 0,00 -0,01 0,08 0,09 -0,17 0,15 0,15 0,04 -0,05 -0,03 
Med 0,06 0,04 0,19 0,14 -0,13 0,18 0,07 -0,01 0,01 0,02 
Econom -0,01 -0,10 -0,24 -0,10 -0,13 -0,09 -0,04 0,13 0,05 0,03 
Engineer -0,26 -0,15 -0,05 -0,03 0,03 -0,07 -0,06 -0,02 -0,10 0,00 
Experience 1,00 0,26 0,22 0,11 0,24 0,21 0,19 0,27 0,15 0,21 
Tenure 0,26 1,00 0,01 -0,18 0,22 -0,16 -0,11 -0,12 -0,10 0,05 
Network.dir 0,22 0,01 1,00 0,57 0,09 0,11 0,18 0,21 0,13 0,04 
Network.ind 0,11 -0,18 0,57 1,00 -0,17 0,22 0,20 0,27 0,39 0,14 
Insider 0,24 0,22 0,09 -0,17 1,00 0,08 0,08 0,10 -0,04 0,15 
Fixed.comp 0,21 -0,16 0,11 0,22 0,08 1,00 0,81 0,58 0,57 0,45 
Total.comp 0,19 -0,11 0,18 0,20 0,08 0,81 1,00 0,64 0,40 0,27 
Variable 0,27 -0,12 0,21 0,27 0,10 0,58 0,64 1,00 0,44 0,41 
Revenue 0,15 -0,10 0,13 0,39 -0,04 0,57 0,40 0,44 1,00 0,49 
Firm,age 0,21 0,05 0,04 0,14 0,15 0,45 0,27 0,41 0,49 1,00 
Source: made by the author 
2.3 Empirical results 
The models analyzed were based on the CEOs characteristics and their influence on the 
innovativeness of the company. Innovativeness is measured as yearly R&D expenditures and 
new patents received over observed year (from 2009 to 2016 year). 
Models for CEOs characteristics relationship with patents received were build using 2 
and 3 years time lag, because it is assumed that new patents in pharmaceutical industry are 
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developing for a long time, not in one year. Model for R&D expenditures was built without time 
lag. 
The estimated coefficients for all independent and control variables importance in all 
three models are presented in the table below.  
 
Table 7.Results of regressions with Fixed effects 
 R.D.Exp NewPatents (lag=2) NewPatents (lag=3) 
Pr(>|t|) Pr(>|t|) Pr(>|t|) 
XAge 0.658926 3.072e-10*** 4.754e-07*** 
XMaster 0.836263 0.0031581** 1.735e-06*** 
XDoctor 0.772852 0.1198090 0.034703* 
XMBA 7.999e-0.5*** 0.0219857* 0.006522** 
XMed 0.068528. 0.0354326* 0.885968 
XEconom 0.022830* 0.0009382*** 1.511e-10*** 
XEngineer 0.148156 0.1057703 0.555968 
XExperience 0.266943 3.625e-11*** 2.929e-05*** 
XTenure 0.225946 0.2623981 0.233936 
XNetwork.dir 0.065838. 0.0049149** <2.2e-16*** 
XNetwork.ind 0.004894** 0.5259903 0.305312 
XInsider 0.017199* 0.0002319*** 0.002078** 
XFixed.comp 0.161227 0.6143493 0.014813* 
XTotal.comp 8.297e-05*** 0.9983594 0.011744* 
XVariable 0.377104 0.7987580 0.596861 
XRevenue 0.050744. <2.2e-16*** 6.395e-14*** 
XFirm.age 0.005511** 0.0002183*** 0.018615* 
F-statistic: 16.8 on 17 and 387 DF 5.2 on 17 and 297 8.6 on 17 and 250 
40 
 
p-value 
R-Squared 
Adj. R-Squared 
<2.22e-16 
0.42501 
0.31655 
DF 
6.1832e-10 
0.46791 
0.36545 
DF 
<2.22e-16 
0.67185 
0.60464 
Source: made by the author 
Significance levels: 
 ‘***’ significant at 0 level 
 ‘**’ significant at 0.001 level 
 ‘*’ significant at 0.01 level 
 ‘.’ significant at 0.05 level 
 The models show that age of CEO has a strong negative relationship with a number of 
new patents obtained in both models: with lag 2 and with lag 3. This variable has the highest 
level of significance. At the same time, this variable is not significant for amount of R&D 
spending that means that R&D expenditures are not connected with the age of CEO. 
As for CEO education, it could be said that received MBA degree has a strong positive 
relationship with R&D expenditures with the highest level of significance. At the same time, the 
relationship with number of new patents is slightly weaker, but also remains positive: 0.001 level 
of significance for model with lag 2 and 0.01 level of significance for model with lag 3. Master 
degree is significant for number of new patents obtained in both models (with lag 2 and 3) and 
relates to it positively. Doctoral degree has positive effect on number of patents obtained in 
model with lag 3 and no not have any effect for other models. 
 Education of CEO is also important factor for all three models. All three models show 
has strong negative effect an education in economics that means that companies innovate less is 
CEO received education in this field. Education in medicine significant and has shown positive 
relationship in models for R&D expenditures and number of patents with lag 2, however the 
level of significance is 0.1 and 0.05 respectively. CEOs education in engineering is not an 
important factor in all three models. 
 CEO experience in pharmaceutical industry has strong positive relationship with 
innovation characteristics in models for number of new patents obtained: variable is significant 
with a highest level of significance, however in model for R&D this variable is not significant. 
Tenure is not important for all three models. 
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 The size of director’s network that shows the number of directors whom CEO knows is 
significant and has a positive relationship with innovativeness in all three models: for R&D 
expenditures the level of significance is 0.5, for new patents obtained with lag 2 and lag 3 the 
levels of significance are 0.001 and 0 respectively. Network of CEO within different industries 
positively significant only for R&D expenditures model: the level of significance is 0.001. 
 The variable that shows that CEO was promoted from the position inside the company is 
significant for all three models with 0.01, 0 and 0.001 levels of significance respectively. This 
variable is positive in all three models. 
 The size of base salary, or fixed compensation, is negatively significant in model for 
amount of R&D expenditures. For other models, this variable is not significant. At the same 
time, total compensation has a strong positive relationship with R&D spending with a 0 level of 
significance and has positive relationship with number of new patents in model with lag 3. 
 Control variables: revenue and firm age significant in all three models.  
 All three models are overall significant: p value for all models is smaller than 0.05. 
2.4 Findings and discussions 
 The goal of the study was to identify the relationship between CEO characteristics and 
innovativeness of the public pharmaceutical companies in European Union measured by R&D 
expenditures and number of new patents obtained. This relationship has been tested by using 
econometric modeling on 55 public pharmaceutical companies in EU from 2009 to 2016 year. 
Based on empirical analysis it is possible to derive conclusions. 
Primarily, the conclusions are drawn based on the hypotheses that have been stated in this 
research. Below in the tables you can see whether hypothesis was accepted or not. 
Table 8. Comparison of hypotheses with obtained results: could hypothesis be accepted or not 
Hypothesis 
Result for R&D 
model 
Result for new 
patents model 
with lag 2 
Result for new 
patents model 
with lag 3 
H1. CEO age negatively relates to 
the company innovativeness. 
Cannot be 
neither 
supported nor 
rejected 
Accepted Accepted 
H2. Innovativeness of companies Accepted Accepted Accepted 
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where CEO has received master’s 
or doctoral degree is higher than 
innovativeness of companies 
where CEO did not receive such 
degrees. 
H3. Innovativeness of companies 
where CEO has received 
education in medical or 
engineering field is higher than 
innovativeness of companies 
where CEO is educated in other 
field. 
Accepted Accepted Accepted 
H4.1 CEO tenure positively 
relates to the company 
innovativeness. 
Cannot be 
neither 
supported nor 
rejected 
Cannot be 
neither supported 
nor rejected 
Cannot be 
neither 
supported nor 
rejected 
H4.2 CEO industry experience 
positively relates to the company 
innovativeness. 
Cannot be 
neither 
supported nor 
rejected 
Accepted Accepted 
H5. The size of network of 
directors and interlocks with 
various industries positively 
relates to the company 
innovativeness. 
Cannot be 
neither 
supported nor 
rejected 
Accepted Accepted 
H6.1 The size of fixed 
compensation negatively relates 
with company innovativeness.  
Cannot be 
neither 
supported nor 
rejected 
Cannot be 
neither supported 
nor rejected 
Accepted 
H6.2 The size of total 
compensation positively relates 
with company innovativeness. 
Accepted 
Cannot be 
neither supported 
nor rejected 
Accepted 
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H7. Innovativeness of companies 
where CEO was promoted from 
the position inside the company is 
higher than innovativeness of 
companies where CEO is 
outsider. 
Accepted Accepted Accepted 
Source: made by the author 
On the one hand, CEO age has a relationship with number of patents that are obtained by 
companies, but on the other hand, this variable is not significant for R&D expenditures. It can 
me assumed, that when CEO is younger, he or she manages effectively all R&D efforts that 
further leads to new patents obtaining: it could be either the right choice of field of R&D efforts 
or effective support and management of R&D department. Thus, it could be said that CEO age 
negatively relates to the company innovativeness. 
In general, companies innovate more if CEO has received masters or doctoral degree than 
if CEO has received only bachelor degree. Among all three variables: master’s degree, MBA and 
doctoral degree the most significant one is MBA degree, being significant for all three regression 
models. Masters degree significant only for new patents obtained and doctoral is significant for 
new patents model with lag 3. In general, it means that company spends more on R&D if CEO 
has master’s degree and receives more new patents if CEO has either master’s of doctoral 
degree. It may be assumed that it is so because CEOs who acquired wide set of knowledge and 
has developed skills during their studies becomes more knowledgeable on innovations and 
consequently innovate more than other CEOs with only bachelor’s degree. 
 The education in medical or engineering field did not show a consistent relationship with 
R&D spending and number of new patents obtained with one exception: medical education is 
important for model for new patents with lag 2. At the same time, the fact whether CEO has an 
education in economics or not is important for all models: all of them showed that if CEO is 
educated in this field, company is innovating less. The most reasonable explanation of this fact is 
that CEOs with background in economics are concerned primarily about financial indicators, 
tend to avoid risky investments and usually follow a cost cutting strategy that may be less 
favorable for innovations development. 
 CEO tenure does not show influence on company innovativeness: being insignificant for 
all models. At the same time, industry experience has positive relationship with the number of 
patents received. It can be assumed that the important factor is that whether CEO has a relevant 
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experience in pharmaceutical industry, but not the number of years spent in CEO position: 
gained professional experience either inside or outside the company will help to acquire valuable 
skills that cannot be entirely covered and gained only through education. 
 Director’s size of network determined by number of total interlocks among all industries 
does not show relationship with R&D spending, but shows influence on the number of new 
patents obtained. At the same time, number of industries where directors work are important for 
amount of R&D spending but does not show a relationship with a number of new patents 
received. These controversial results could be explained in the next way: the total size of 
director’s network positively relates to company innovativeness and lead to increasing number of 
patents. All director’s connections contribute to joint ventures creation, technology transfer as 
well as to receiving a better view of strategies for R&D investments and knowing the key of 
success based on experience of other directors. Thus, the bigger the network is, the more patents 
in average company will receive in 2, 3 year-period. 
 The fixed compensation does not show a strong influence, being significant only for 
number of new patents received with lag 2. At the same time, for this model variable has 
negative effect that supports the hypothesis. On contrary, the size of total compensation has a 
relationship with company innovativeness being significant for R&D spending and for one of the 
models for new patents. That means that the more CEO receives in absolute values, the more 
innovative company is. It could be implied that CEOs in pharmaceutical industry are aware of 
innovations role in company development, and realize that the more they will innovate, the 
bigger remuneration they will receive. It may be concluded that the hypothesis about fixed part 
role can be neither supported, nor rejected, while it could be said that total remuneration 
positively relates with company innovativeness. 
 Innovativeness of companies where CEO was promoted from the position inside the 
company shows consistent significant influence on all dependent variables. It could be inferred 
that if CEO has been promoted from the position inside he or she may feel more committed to 
the company and know better the where the processes and products should be improved as well 
as where to innovate. Thus, it can be said that innovativeness of companies where CEO was 
promoted from the position inside the company is higher than innovativeness of companies 
where CEO is outsider. 
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2.5 Managerial implications 
Companies’ growth and development in pharmaceutical industry is driven by 
innovations. Different factors that can predetermine the innovative development is among the 
most researched topics nowadays. One of the factors that can play role in innovative 
development is CEO characteristics. 
Companies are interested in this in particular when they should choose and assign new 
manager on executive position. They tend to analyze how the candidate will fit to the company, 
what actions may be predicted and expected, what is his or her psychological portrait, etc. 
Especially it is important when company choose who will become a new CEO. CEO is the main 
executive in a company. The primary responsibility of CEO is to make major corporate 
decisions, to plan and manage all high-level operations of a company and to communicate 
between the board of directors and corporate operations. That is why company pays so much 
attention when decide who will become a new CEO. 
Researches usually use as a CEO characteristics his or her age, gender, education, 
experience, network. At the same time, it could not be said that there is a perfect portrait of CEO 
for all companies in all industries. In fact, each industry has its own specifics and companies in 
different industries should be led by CEO with some special “perfect portrait”.  Pharmaceutical 
industry is not an exception: it has a lot of specifics that distinguish this industry from others. 
Results of this research have not only theoretical contribution in the existing line of research, but 
also imply useful managerial implications for companies in pharmaceutical industry. 
This research is expected to attract attention to the CEO characteristics before he or she is 
assigned to the CEO position in the company. The results of empirical analysis shows that 
different CEO characteristics have various relationships with company innovativeness, measured 
by R&D spending and number of new patents obtained. Thus, personal CEO characteristics 
should be taken into consideration when assigning new CEO.  
When assigning a new CEO company should pay attention on several characteristics: 
 CEO age. The younger CEO is, the more new patents company receives in next 2 and 3 
years. Thus, while choosing among younger and older candidate to CEO position with similar 
characteristic, company should prefer the younger one. 
CEO field of education. If candidate to CEO position received education in economics, 
company will innovate less. Thus, if the company wants to innovate more, is should avoid 
assigning a director with background in economics. 
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CEO level of education. If candidate received master’s and doctoral level of education, 
company will innovate more. While choosing among candidate with master’s or doctoral degree 
and the one with bachelor degree it is better to prefer the one with master’s of doctoral degree. 
Experience. The longer candidate is working in pharmaceutical industry, the more patents 
company receives when candidate became a CEO in company. Thus, it is better to hire candidate 
with relevant experience. 
Personal network. The more directors candidate to CEO position knows, the more 
innovative company will become. It is preferable to hire director with broad personal network. 
Hiring from inside. Study shows that if CEO was promoted from the position inside the 
company is more innovative that if CEO is outsider. Thus, it is better to hire CEO from inside. 
Remuneration. The high total remuneration corresponds to higher company 
innovativeness. Thus, the absolute amount of compensation does matter. 
At the same time, it should be mentioned that these recommendations are rational when 
company in pharmaceutical industry wants to pursuit the innovative strategy. If the main goal is 
financial performance, recommendations may change. 
 
2.6 Research limitations 
The goal of this research paper was to identify the relationship between CEO 
characteristics and innovativeness of the public pharmaceutical companies in European Union 
measured by R&D expenditures and number of new patents obtained. The goal was achieved and 
research has both theoretical contributions and managerial implications. At the same time, this 
research has some limitations that can in turn shape the direction of future research. 
The first limitation is that the sample does not include all public pharmaceutical 
companies due to unavailability of data needed. It may be assumed that by adding data about 
other 15 companies other results may be obtained. 
Secondly, due to the fact that data sample includes only public companies and the number 
of non-public pharmaceutical companies is significant, further researches may include non-
public companies into research sample, if data will be available. Because the number of non-
public companies in much bigger than the number of public companies, results may change 
significantly: some variables may become significant and some, on contrary, won’t be 
significant. 
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Furthermore, the list of CEO characteristics can be extended. For example, director’s 
business and his or her company ownership may be included in the sample of independent 
variables. 
Although there are some research limitations, the results that have been obtained based 
on sample of 55 public pharmaceutical companies in EU have clear managerial implications. 
Discussed limitations do not undermine results of empirical analysis but rather creases possible 
direction for future research in this field. Companies in pharmaceutical industry that are 
interested in innovation development can use results obtained. 
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Conclusion 
 Nowadays, innovations in pharmaceutical industry are more demanded than ever before. 
Various healthcare institutions have highly qualified employees who able to develop and 
implement innovations and manage large innovative projects. Innovations in pharmacy enable to 
improve the quality of medical care, health care, disease prevention. By creating innovations 
companies may obtain a competitive advantage that will boost revenues and may also cut costs: 
that is why topic of innovations in pharmaceutical industry is highly actual. In innovations 
development the creation of the highly efficient executive management team is crucial. That is 
why it is highly important to assign to the CEO position person, who will perfectly fit to this 
role. 
 This research paper was aimed to identify the relationship between Chief Executive 
Officer personal characteristics and innovativeness of the public pharmaceutical companies in 
European Union measured by R&D expenditures and number of new patents obtained. More 
specifically, the research question that has been stated was about which CEO characteristics are 
important when company in pharmaceutical industry wants to increase its innovativeness and? If 
important, than in what extend? In particular, this research covered CEO characteristics such as 
age, educational level and field, tenure, level of fixed and total remuneration, hiring from inside 
of outside and director’s network. 
 To achieve stated goal a list of objectives was stated. The logic of this research 
corresponds to the order of objectives that have been set in the beginning. At first, the literature 
review on the topic of innovations was done: innovations definition, the role for companies in 
pharmaceutical industry was analyzed. After, the topic of corporate governance and CEO role 
was covered: the characteristics of CEO that can be significant were determined and hypotheses 
were stated. Finally, the empirical models were determined and tested in order to obtain results 
about the existence of the relationship between personal characteristics of CEO and company 
innovativeness. After the results have been obtained managerial implications were formulated.  
 Existing researches claims that personal characteristics of CEO have an impact on 
different sides of how company operates. Researchers believe that CEO characteristics are 
important also have an impact, however, sometimes results are controversial, because empirical 
analysis are conducted on deferent data and sample. For instance, CEO’s economic expertise is 
valuable for company because it leads to effective planning and controlling processes, accurately 
developed budgets. If such CEO understands the innovations long-term value he or she may also 
pay a high attention to them. At the same time CEO’s economic background usually leads to cost 
cutting that may be less favorable for innovative projects [Jeanjean, Stolowy 2009]. Such duality 
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is true for many CEO characteristics that is why this research can be valuable because it provides 
an insights for companies in pharmaceutical industry: who better suits to the CEO position in 
pharmacy. To conclude, the following research contributes to the existing pool of literature on 
the topic of corporate governance because it creates useful managerial implications for 
companies in pharmaceutical industry. 
 In this empirical study, the data about 55 pharmaceutical companies in EU was gathered. 
Data was collected from Tomson Reuters Database, Bloomberg profiles, annual reports for 
companies and their websites for the 8-year period from 2009 to 2016. 
 The results of the study show that some characteristics of CEO have a relationship with 
company innovativeness, measured by R&D expenditures and number of new patents obtained 
in 2, 3 year period. These characteristics that are considered to be important have to be taken into 
consideration when CEO assigning. The results obtained by conducting regression analysis 
support the following conclusions: 
1. Young CEOs tend to facilitate to company innovativeness in pharmaceutical industry. 
2. CEOs with education in economics tend to facilitate less to innovative development in 
pharmaceutical company 
3. If CEO received master’s and doctoral level of education, pharmaceutical company 
innovates more than if CEO has received only bachelor degree 
4. The longer CEO is working in pharmaceutical industry, the more patents company 
receives 
5. The more directors CEO knows the more innovative company is. 
6. If CEO was promoted from the position inside the company is more innovative that if 
CEO is outsider 
7. The high total remuneration corresponds to higher company innovativeness. 
 This research paper has a theoretical contribution to the existing pool of literature about 
corporate governance by providing more insights about role of CEO characteristics in company 
innovativeness measured by R&D expenditures and number of new patents obtained. Also, it 
creates a basis for further research, shaping the direction of possible analysis. 
 Moreover, research has a managerial implications, based on which the important decision 
about CEO assignment could be made. To maximize the innovation potential of pharmaceutical 
company CEOs preferable characteristics has been discussed. 
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 At the same time research has some limitations. Firstly, not all pharmaceutical companies 
are included in the sample that can have a relationship with obtained results. Also, non-public 
companies dominate on the market in terms of number of companies and if they would be 
included into empirical models, the implications would be more valuable for a whole 
pharmaceutical market. Furthermore, the list of CEO characteristics can be extended. 
 To conclude, the relationship of personal CEO characteristics and company 
innovativeness was analyzed. Despite research has some limitations, valuable conclusions as 
well as theoretical and managerial implications may be derived. 
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Appendix 2. Result of Model for New Patents with lag 2 
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Appendix 3. Result of Model for New Patents with lag 3 
 
 
 
